Skip over main navigation
  • Sign up
  • Log in
  • Basket: (0 items)
Hadassah Australia Medical Research Collaboration (HAMRC)
  • Facebook
  • Instagram
Donate
Menu
  • About us
    • Who we are
    • Vision, Mission, Purpose
    • Israel
    • Our team
      • Board
      • Scientific Advisory Committee
      • Development Committee
      • Staff
  • Research
    • Current research
    • Need for collaborative research
    • Partnering with Israel
    • Research partnerships
  • Our impact
    • The difference we can make together
  • Get involved
    • Donate
    • Other ways to give
      • Pledge Gifts
      • Gifts in Wills
    • Project Enquiries
  • News and events
    • News
    • Upcoming Events
    • Webinars
    • Current newsletter
  • Admin
    • Log in
  • Basket: (0 items)
  1. About us
  2. Our team
  3. Scientific Advisory Committee

Scientific Advisory Committee

To assist the board to assess high value research projects, our Scientific Advisory Committee is comprised of prominent experts in medicine, research and higher education sectors.

Dr Russell Basser

Expand

Dr Russell Basser is a qualified physician and spent 10 years in an academic clinic Medical Oncology/Haematology. Since joining CSL (a leading biopharmaceutical company specialising in plasma-derived, recombinant protein therapeutics and influenza vaccines) in 2001, he has worked in a wide range of therapeutic areas and overseen clinical development, clinical operations, regulatory affairs, drug safety and biometrics/medical writing. He was responsible for globalising the Clinical R&D group and rebuilding the development capabilities in Japan and in 2014 was appointed to the role of Chief Medical Officer in Melbourne, Australia. He recently took up the role of SVP R&D at Seqirus (a fully owned subsidiary of CSL Ltd), a new specialist influenza vaccine company formed from the merger of bioCSL which acquired influenza vaccine assets of Novartis. Seqirus is the second largest influenza vaccine company globally.

Published: 25th November, 2019

Updated: 2nd November, 2020

Author: Lee Robinson

Related topics:
  • Scientific Advisory Committee
  • Team
Share this page
  • Email
  • Facebook
  • Twitter

Alan Liddle

Expand

Alan Liddle has over 30 years' experience in developing and commercialising medical and biological therapeutics and over 30 years’ research & executive management experience in the medical and the biotechnology research sector encompassing immunology and bio-therapeutics for cancer and auto-immune diseases, cardiology, neuroplasticity, the microbiome, regenerative medicine & rehabilitation. Alan is Executive Director of Sangui Bio a company he cofounded in 2014. Sangui is commercialising its discoveries in the role of red blood cells in immune system activation and regulation. Alan co-founded and was CEO & Director of Immune System Therapeutics Ltd from 2001 to 2011. He was also the Founder, CEO & Director of MicroMedical Industries Limited from 1986. He built the company from a start-up to an ASX listed, international provider of medical monitoring and diagnostic products and a developer of artificial heart technologies. Prior to his biomedical career Alan was a neuropsychologist researcher at the University of Sydney specialising in rehabilitation of patients following traumatic brain injuries. He was the co-inventor of the rehabilitation software program: Dynamind3D. Alan holds a BA (Hons) from the University of Sydney and MBA from the University of NSW and is a fellow of the Australian Institute of Company Directors

Published: 2nd December, 2019

Updated: 2nd November, 2020

Author: Lee Robinson

Related topics:
  • Scientific Advisory Committee
  • Team
Share this page
  • Email
  • Facebook
  • Twitter

Dr Gabby Goldberg

Expand

Dr Gabby Goldberg is Operations Manager of Synthesis Research and its investee companies Anaxis Pharma and Catalyst Therapeutics – joint ventures with the Walter and Eliza Hall Institute of Medical Research. She has over 15 years’ experience leading translational research. Her PhD with Prof. Richard Boyd at Monash University resulted in several high-impact publications and a multi-centre clinical trial. She went on to do post-doctoral fellowships in translational immunology at Memorial Sloan-Kettering Cancer Center and Baylor Institute of Immunology Research. Upon her return to Australia, she accepted a Senior Research Officer position with Prof. Ian Wicks at the Walter and Eliza Hall Institute. Working on a CSL Ltd. funded project, she undertook and coordinated a preclinical drug development program involving clinical, academic and industry staff. A year after joining the lab, she was awarded an NHMRC Career Development Fellowship (Industry) which afforded her the opportunity to work on secondment at CSL and play an integral role in the research leading up to the IND filing of a novel drug targeting inflammatory diseases.

 

Published: 13th January, 2020

Updated: 2nd November, 2020

Author: Lee Robinson

Related topics:
  • Scientific Advisory Committee
Share this page
  • Email
  • Facebook
  • Twitter

Dr Michal Milgrom-Hoffman

Expand

Dr Michal Milgrom-Hoffman is currently a Research Fellow in the Department of Biochemistry, Latrobe University and a member of the Humbert Cancer biology, cell polarity and tissue architecture research team under Prof Patrick Humbert looking at how cell asymmetry and tissue organization can regulate cancer initiation, progression and metastasis with the ultimate aim to devise therapeutics to help tumours ‘reorganize’ themselves, thereby stopping the cancer’s growth and spread. The team works closely with cancer clinicians, pathologists, immunologists, a geneticist and a crystallographer.

Published: 13th January, 2020

Updated: 2nd November, 2020

Author: Lee Robinson

Related topics:
  • Scientific Advisory Committee
Share this page
  • Email
  • Facebook
  • Twitter

Prof Jeffrey Zajac AO

Expand

Prof Jeffrey Zajac is Professor and Head of the University of Melbourne, Department of Medicine at Austin Health. He is a Clinical Endocrinologist and General Physician with research interests in molecular endocrinology. He is Chairman of Medicine and Director of the Department of Endocrinology at Austin Health. Prof Zajac trained in Medicine at the University of Melbourne and undertook a PhD in the Department of Medicine, Austin & Repatriation Medical Centre. Following postdoctoral work in the Endocrine Genetics Unit at Massachusetts General Hospital, Boston, he returned to the University of Melbourne initially at Royal Melbourne Hospital and now Austin Health. His research group has embarked on a major research program investigating the effect of androgen deprivation therapy in patients with prostate cancer. These investigations include effects on bone, muscle, cardiovascular risk and metabolic state. He also heads a molecular endocrinology group investigating the androgen receptor using genetically modified mice.

Published: 13th January, 2020

Updated: 2nd November, 2020

Author: Lee Robinson

Related topics:
  • Scientific Advisory Committee
Share this page
  • Email
  • Facebook
  • Twitter
Back to top

Showing 10 of 5

Latest

  • What are organoids? Welcome to a revolution in basic medical science

    What are organoids? Welcome to a revolution in basic medical science

    Basic science research is experiencing a revolution with the creation of organoids, 3D miniature cellular, and functional replicas of our bodily organs.

  • Hadassah collaborates to develop a face mask that kills the coronavirus

    Hadassah collaborates to develop a face mask that kills the coronavirus

    The mask, which has antiviral and antibacterial properties, contains a disinfectant that has proven 99.99% effective in killing the virus.

  • First in Israel: Hadassah corrects irregular heartbeat with new method

    First in Israel: Hadassah corrects irregular heartbeat with new method

    An innovative procedure to treat irregular heartbeats is enabling surgeons to access areas of the heart that, up until now, have been impossible to reach.

  • Hadassah and Neurogenesis announce groundbreaking results from phase 2 MS Study

    Hadassah and Neurogenesis announce groundbreaking results from phase 2 MS Study

    A Phase 2 study at Hadassah Hospital has revealed significant clinical improvements in patients with progressive multiple sclerosis.

Most read

  • At risk: Exploring the link between prematurity and chronic kidney disease

    At risk: Exploring the link between prematurity and chronic kidney disease

    Catch up on this important webinar bringing you expert and personal insights on the link between prematurity and chronic kidney disease.

  • Researching a way forward

    Researching a way forward

    “We have a chance to do something significant in the medical field because of the calibre of people who are attracted to the work we do,” says Dr Russell Basser, Chair of the HAMRC Scientific Advisory Committee.

  • Israel: The Connection

    Israel: The Connection

    There is virtually no area of medical research to which Israel has not made significant contributions - cardiology, genetics, neurology and ophthalmology are but a few that have benefited.

  • Vision, mission, purpose

    Vision, mission, purpose

    The HAMRC Foundation links the brightest researchers at Hadassah Hospital in Israel with their colleagues in Australia in order to solve the most pressing health issues facing the world.

  • Our board

    Our board

    The board oversees HAMRC’s mission including the assessment and funding of high-quality medical research collaborations which will ultimately lead to improve patient outcomes by accelerating the pace of biomedical discovery and the translation of medical breakthroughs into novel therapeutics and diagnostics.

  • Webinar—Coping with COVID: Safeguarding your mental health in the age of COVID-19

    Webinar—Coping with COVID: Safeguarding your mental health in the age of COVID-19

    Register now for this live webinar bringing you expert tips and insights from some of Australia and Israel's leading mental health professionals.

  • Drug developed by Hadassah doctor helps severely ill Covid-19 patients

    Drug developed by Hadassah doctor helps severely ill Covid-19 patients

    Hadassah Hospital successfully treated five seriously-ill COVID-19 patients using an experimental treatment. All five patients tested negative to coronavirus and have now been discharged.

  • Save the Next Steve Jobs from Terminal Pancreatic Cancer

    Save the Next Steve Jobs from Terminal Pancreatic Cancer

    Save the next Steve Jobs from terminal pancreatic cancer; harness Australia's medical know-how and Israel's clinical trial advantage.

  • Example - Where your money goes

    Earn your supporters' trust by being transparent and making the impact of their support clear

  • Terms and Conditions

Sign up for our newsletter

Please enter your first name
Please enter your last name
Please enter your email address Please enter a valid email address (e.g. [email protected])

Find us

Registered Office
PO Box 2400
Caulfield
Vic 3161

+61 (3) 9272 5600
[email protected]

Links

  • Sitemap
  • Accessibility
  • Terms & Conditions
  • Privacy Policy

Follow us

  • Facebook
  • Instagram

Registered as Charity number 90629423641